Programmed Cell Death Ligand 1 Expression in Cytological and Surgical Non-Small Cell Lung Cancer Specimens in Association with EGFR Mutation and Overall Survival: A Single-Institution Experience

Basit Öğe Kaydı
dc.contributor.authorSayman Gokal, Elif
dc.contributor.authorVardar Aker, Fugen
dc.contributor.authorKus Silav, Zuhal
dc.contributor.authorOven, Bala Basak
dc.date.accessioned2024-08-04T20:52:16Z
dc.date.available2024-08-04T20:52:16Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: The aim of this study was to evaluate programmed cell death ligand-1 (PD-L1) expression and the relationship between driver mutations and survival analysis in advanced-stage non-small cell lung carcinoma (NSCLC). Material and Method: A total of 122 advanced-stage NSCLC patients were included in this retrospective study. The patients were diagnosed based on cytological examination and histopathological analysis of biopsy or resection material that had undergone at least 1 molecular analysis. The expression of PD-L1 in tumors and tumor-infiltrating lymphocytes (TIL) was scored and compared with age, sex, organ, biopsy method, tumor subtype, driver mutation status, and overall survival data. Results: There was no statistically significant difference between PD-L1-positivity and age, gender, location, pattern, or pathological diagnosis of the type of sample. When the threshold value for PD-L1 IHC evaluation was accepted as 1% and 50%, the rate of positivity was 19.7% and 7.4%, respectively. Conclusion: Since there is a wide range of positivity rates reported in the literature, we could not reach a conclusion as to whether the PD-L1-positivity rate we observed was high or low. There is a need for comparative studies where the technique, clones, threshold values, and phases are homogenized. There is an inverse correlation between the EGFR-mutant population and PD-L1 positivity. In terms of overall survival, no relationship was found between PD-L1 positivity, the presence of TIL, and EGFR mutation status.en_US
dc.identifier.doi10.5146/tjpath.2022.01572
dc.identifier.endpage274en_US
dc.identifier.issn1018-5615
dc.identifier.issn1309-5730
dc.identifier.issue3en_US
dc.identifier.pmid35642342en_US
dc.identifier.scopus2-s2.0-85137137727en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage261en_US
dc.identifier.urihttps://doi.org/10.5146/tjpath.2022.01572
dc.identifier.urihttps://hdl.handle.net/11616/100867
dc.identifier.volume38en_US
dc.identifier.wosWOS:000890035800009en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFederation Turkish Pathology Socen_US
dc.relation.ispartofTurkish Journal of Pathologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEpidermal growth factor receptoren_US
dc.subjectNon-small cell lung canceren_US
dc.subjectProgrammed cell death ligand-1en_US
dc.subjectSurvivalen_US
dc.titleProgrammed Cell Death Ligand 1 Expression in Cytological and Surgical Non-Small Cell Lung Cancer Specimens in Association with EGFR Mutation and Overall Survival: A Single-Institution Experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu